AYTU

Aytu BioPharma, Inc. (AYTU) | Rumor.io

Aytu BioPharma

AYTU

Attention (50-day avg)0%

Attention rank (50-day avg)#1,915

Bullish sentiment (50-day avg)15%

Price to earnings ratio-1

Market capitalization23.6M

Earnings per share-1.16

Dividend yield (TTM)—

Revenue (annual)66.4M

Net income (annual)-13.6M

Social

What share of all stock conversation is about AYTU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 22

Aytu BioPharma's Q4 2026 revenue increased 6.4% to $16.1M, beating estimates by 31.2%.
The company's Adjusted EBITDA for Q4 2026 was $0.5M, with a net loss of $0.00, breakeven.
Aytu BioPharma's EXXUA prescription count rose 138% QoQ, with revenue reaching $3.9M, a 64% QoQ increase.

Generated by AI

Sentiment

Of the messages about AYTU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	40%	40% new	48.96% -9.15
Bearish	—	60%	60% -40	51.04% +9.15

Bullish· Jun 6

Aytu BioPharma's share price has the potential to reach $100 by the end of the year.
The company's recent quarter was profitable, with revenues of over $18M, indicating a $72M annual run rate and a potential share price of $4.50.
Aytu BioPharma is well-positioned to capitalize on the 22 billion US market, with its recent offering and management's efforts to drive growth.

Bearish· May 15

The stock has already peaked and is expected to decline, with some predicting a drop to $10 by the end of the next week.
The company's financial situation is seen as precarious, with concerns about dilution and a halt in trading.
The stock's momentum is expected to be short-lived, with some predicting a sharp decline as soon as the market makers' quota is reached.

Generated by AI

Topics

Of the messages about AYTU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	—	41.18%	41.18%	17.91%
Announcements	—	58.82%	58.82%	68.66%
Analysts	—	0%	0%	1.49%
Controversies	—	0%	0%	2.99%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	8.96%

Earnings· Feb 11

Aytu BioPharma, Inc. reported a net loss of $9.5 million in Q2 2021, missing EPS estimates by $0.28.
The company's Q2 revenue of $15.15 million beat estimates by $2.9 million, a 377% year-over-year increase.
Aytu BioPharma ended the quarter with $62.3 million in cash, and its merger agreement with Neos Therapeutics is expected to create a combined $100 million revenue specialty pharmaceutical company.

Announcements· Jan 6

AYTU reported a record quarterly net revenue of $27.7 million, driven by 34% growth in the Rx segment.
The company also achieved positive adjusted EBITDA for the quarter of $1.4 million.
AYTU has implemented leadership changes to focus on commercial operations.

Technical Analysis· Jun 21

$AYTU is likely to move higher if it closes above the 50-day moving average.
A breakout of the falling wedge pattern could send $AYTU to $16-$20, with a double bottom formation also indicating an uptrend.
Breaking above $5.50 could trigger a significant move in $AYTU, with some analysts suggesting it could reach as high as $8.75.

Generated by AI

Community

Of the messages about AYTU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	78.48%	88.38%	75.49%
Newcomers	—	21.52%	11.62%	24.51%

Regulars· Sep 28

AYTU BioPharma's stock has seen a rapid price rise, up 21% since the previous trading day, and is currently trading at $2.32, with high relative volume (124 RVOL).
AYTU BioPharma has reported record revenues, record prescriptions, and the highest adjusted EBITDA in company history for the fourth quarter of fiscal year 2023.
The complete float of AYTU BioPharma's stock, 2.6M shares, has been traded in a single day, with 3.1M shares traded overall, indicating significant investor interest and market activity.

Newcomers· Sep 23

$AYTU's EXXUA antidepressant launch could be a game-changer in treating depression, with a potential competitive edge over existing treatments due to fewer side effects.
Aytu BioPharma's pivot to commercializing EXXUA may fundamentally change the company's narrative, shifting focus from operational optimization to high-stakes commercial launch.
Aytu BioPharma's fiscal 2025 full-year and fourth-quarter results show strong double-digit growth in its ADHD and Pediatric portfolio, with a return to profitability, but next quarter's results are being eyed by investors.

Generated by AI

News

Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary

Moby summary of Aytu BioPharma, Inc.'s Q4 2026 earnings call

6d agoYahoo Finance

Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...

Aytu BioPharma Inc (AYTU) posted $16.1 million in Q4 FY2026 revenue as EXXUA prescriptions surged 138% and the company swung to positive adjusted EBITDA of $0.5 million.

7d agoYahoo Finance

Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast

7d agoInvesting.com

Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call - Aytu BioPharma (NASDAQ:AYTU)

On Tuesday, Aytu BioPharma (NASDAQ:AYTU) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time

7d agoBenzinga

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates

7d agoYahoo Finance

Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4%

7d agoInvesting.com

Also Discussed

Investors talking about AYTU also mention

#	Name	Attention
1	Co-Diagnostics Inc.CODX	0%+0
2	iBio, Inc.IBIO	0%0
3	Biomerica Inc.BMRA	0%0
4	GHSI - Guardion Health Sciences, Inc.	——
5	NVCN - Neovasc Inc.	——
6	Top Ships Inc.TOPS	0%+0
7	Remark Holdings Inc.MARK	0%0
8	YTEN - Yield10 Bioscience, Inc.	——
9	THMO - ThermoGenesis Holdings, Inc.	——
10	Seanergy Maritime Holdings Corp.SHIP	0%0

Aytu BioPharma, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on prescription therapeutics and consumer health products. Aytu BioPharma primarily serves patients with complex central nervous system conditions, with products used in the treatment of major depressive disorder and attention deficit-hyperactivity disorder. Its current portfolio also includes medicines for allergic conditions and fluoride-based pediatric supplement products for infants and children. The company markets its prescription products through third-party channels and also offers consumer health items directly to consumers. Based in Denver, Colorado, Aytu BioPharma operates as a commercial-stage healthcare company with a portfolio aimed at addressing ongoing medical needs across psychiatry, pediatrics, and supportive care.

Website

Location

Denver Corporate Center III

Denver, CO, 80237

United States

Social

What share of all stock conversation is about AYTU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 22

Aytu BioPharma's Q4 2026 revenue increased 6.4% to $16.1M, beating estimates by 31.2%.
The company's Adjusted EBITDA for Q4 2026 was $0.5M, with a net loss of $0.00, breakeven.
Aytu BioPharma's EXXUA prescription count rose 138% QoQ, with revenue reaching $3.9M, a 64% QoQ increase.

Generated by AI

Sentiment

Of the messages about AYTU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	40%	40% new	48.96% -9.15
Bearish	—	60%	60% -40	51.04% +9.15

Bullish· Jun 6

Aytu BioPharma's share price has the potential to reach $100 by the end of the year.
The company's recent quarter was profitable, with revenues of over $18M, indicating a $72M annual run rate and a potential share price of $4.50.
Aytu BioPharma is well-positioned to capitalize on the 22 billion US market, with its recent offering and management's efforts to drive growth.

Bearish· May 15

The stock has already peaked and is expected to decline, with some predicting a drop to $10 by the end of the next week.
The company's financial situation is seen as precarious, with concerns about dilution and a halt in trading.
The stock's momentum is expected to be short-lived, with some predicting a sharp decline as soon as the market makers' quota is reached.

Generated by AI

Topics

Of the messages about AYTU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	—	41.18%	41.18%	17.91%
Announcements	—	58.82%	58.82%	68.66%
Analysts	—	0%	0%	1.49%
Controversies	—	0%	0%	2.99%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	8.96%

Earnings· Feb 11

Aytu BioPharma, Inc. reported a net loss of $9.5 million in Q2 2021, missing EPS estimates by $0.28.
The company's Q2 revenue of $15.15 million beat estimates by $2.9 million, a 377% year-over-year increase.
Aytu BioPharma ended the quarter with $62.3 million in cash, and its merger agreement with Neos Therapeutics is expected to create a combined $100 million revenue specialty pharmaceutical company.

Announcements· Jan 6

AYTU reported a record quarterly net revenue of $27.7 million, driven by 34% growth in the Rx segment.
The company also achieved positive adjusted EBITDA for the quarter of $1.4 million.
AYTU has implemented leadership changes to focus on commercial operations.

Technical Analysis· Jun 21

$AYTU is likely to move higher if it closes above the 50-day moving average.
A breakout of the falling wedge pattern could send $AYTU to $16-$20, with a double bottom formation also indicating an uptrend.
Breaking above $5.50 could trigger a significant move in $AYTU, with some analysts suggesting it could reach as high as $8.75.

Generated by AI

Community

Of the messages about AYTU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	78.48%	88.38%	75.49%
Newcomers	—	21.52%	11.62%	24.51%

Regulars· Sep 28

AYTU BioPharma's stock has seen a rapid price rise, up 21% since the previous trading day, and is currently trading at $2.32, with high relative volume (124 RVOL).
AYTU BioPharma has reported record revenues, record prescriptions, and the highest adjusted EBITDA in company history for the fourth quarter of fiscal year 2023.
The complete float of AYTU BioPharma's stock, 2.6M shares, has been traded in a single day, with 3.1M shares traded overall, indicating significant investor interest and market activity.

Newcomers· Sep 23

$AYTU's EXXUA antidepressant launch could be a game-changer in treating depression, with a potential competitive edge over existing treatments due to fewer side effects.
Aytu BioPharma's pivot to commercializing EXXUA may fundamentally change the company's narrative, shifting focus from operational optimization to high-stakes commercial launch.
Aytu BioPharma's fiscal 2025 full-year and fourth-quarter results show strong double-digit growth in its ADHD and Pediatric portfolio, with a return to profitability, but next quarter's results are being eyed by investors.

Generated by AI

Aytu BioPharma

Social

Sep 22

Bullish· Jun 6

Bearish· May 15

Earnings· Feb 11

Announcements· Jan 6

Technical Analysis· Jun 21

Regulars· Sep 28

Newcomers· Sep 23

Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary

Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...

Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast

Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call - Aytu BioPharma (NASDAQ:AYTU)

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates

Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4%

Also Discussed

Aytu BioPharma, Inc.

Company Information

Location

Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary

Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...

Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast

Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call - Aytu BioPharma (NASDAQ:AYTU)

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates

Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4%

Also Discussed

Social

Sep 22

Bullish· Jun 6

Bearish· May 15

Earnings· Feb 11

Announcements· Jan 6

Technical Analysis· Jun 21

Regulars· Sep 28

Newcomers· Sep 23